<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Endocrinol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Endocrinol</journal-id><journal-id journal-id-type="publisher-id">IJE</journal-id><journal-title-group><journal-title>International Journal of Endocrinology</journal-title></journal-title-group><issn pub-type="ppub">1687-8337</issn><issn pub-type="epub">1687-8345</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6350596</article-id><article-id pub-id-type="doi">10.1155/2019/7429187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>
<italic>IRF7</italic> Gene Variations Confer Susceptibility to Autoimmune Thyroid Diseases and Graves' Ophthalmopathy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8056-3107</contrib-id><name><surname>Yao</surname><given-names>Qiuming</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>An</surname><given-names>Xiaofei</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mu</surname><given-names>Kaida</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1466-5428</contrib-id><name><surname>Song</surname><given-names>Ronghua</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Peilong</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1700-4695</contrib-id><name><surname>Zhang</surname><given-names>Jin-an</given-names></name><email>zhangjinan@hotmail.com</email><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Endocrinology, Jinshan Hospital of Fudan University, No. 1508 Longhang Road, Jinshan District, Shanghai 201508, China</aff><aff id="I2">
<sup>2</sup>Department of Endocrinology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210023, China</aff><aff id="I3">
<sup>3</sup>Department of Endocrinology, Shanghai University of Medicine &amp; Health Sciences Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong District, Shanghai 201318, China</aff><aff id="I4">
<sup>4</sup>Department of General Surgery, Jinshan Hospital of Fudan University, No. 1508 Longhang Road, Jinshan District, Shanghai 201508, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Flavia Magri</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2019</year></pub-date><volume>2019</volume><elocation-id>7429187</elocation-id><history><date date-type="received"><day>21</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#169; 2019 Qiuming Yao et al.</copyright-statement><copyright-year>2019</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The objective of this study was to investigate whether <italic>IRF7</italic> polymorphisms are associated with autoimmune thyroid diseases (AITDs). We selected three single nucleotide polymorphisms (SNPs) of <italic>IRF7</italic>, namely, rs1061501, rs1131665, and rs1061502 for genotyping using PCR-based ligase detection reaction (LDR) method in a total of 1659 participants (592 with Graves' disease, 297 with Hashimoto's thyroiditis, and 770 healthy controls). Gene-disease and genotype-clinical phenotype associations were evaluated for the three SNPs. Our results showed that the AG genotype and the minor allele G frequency of rs1131665 and rs1061502 in AITD patients were both higher than those of the controls (rs1131665: AG genotype: <italic>P</italic> = 0.017, OR = 1.968; allele G: <italic>P</italic> = 0.018, OR = 1.946; rs1061502: AG genotype: <italic>P</italic> = 0.029, OR = 1.866; allele G: <italic>P</italic> = 0.031, OR = 1.847). Subgroup analysis also showed that the AG genotype and the minor allele G frequency of rs1131665 and rs1061502 in Graves' disease patients were both higher than those of the controls (rs1131665: AG genotype: <italic>P</italic> = 0.015, OR = 2.074; allele G: <italic>P</italic> = 0.016, OR = 2.048; rs1061502: AG genotype: <italic>P</italic> = 0.034, OR = 1.919; allele G: <italic>P</italic> = 0.035, OR = 1.898). Furthermore, the allele G frequency of rs1061501 was associated with Graves' ophthalmopathy (<italic>P</italic> = 0.035, OR = 1.396). No significant difference in <italic>IRF7</italic> polymorphisms was found between Hashimoto's thyroiditis patients and controls. Our study has revealed for the first time that <italic>IRF7</italic> is a susceptibility gene for AITD, especially for Graves' disease and Graves' ophthalmopathy.</p></abstract><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81471004</award-id><award-id>81670722</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Autoimmune thyroid diseases (AITDs) are a type of T cell-mediated organ-specific autoimmune diseases, the prevalence of which is more than 5% and result from loss of immune tolerance or autoimmune attack to the thyroid itself; they mainly include Graves' disease (GD) and Hashimoto's thyroiditis (HT) [<xref rid="B1" ref-type="bibr">1</xref>&#8211;<xref rid="B3" ref-type="bibr">3</xref>]. The main cause of clinical hyperthyroidism and hypothyroidism is GD and HT, respectively [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>]. Hyperthyroidism in GD is attributed to thyroid-stimulating autoantibodies to the TSH receptor, whereas hypothyroidism in HT is related to autoantibodies against thyroid peroxidase and thyroglobulin [<xref rid="B5" ref-type="bibr">5</xref>]. The pathogenesis of AITD is thought to be the interaction between susceptibility genes and environmental factors. Recent studies have identified a number of susceptibility loci for AITD, including <italic>CD40</italic> [<xref rid="B6" ref-type="bibr">6</xref>], interleukin 10 [<xref rid="B7" ref-type="bibr">7</xref>], miR-499a and miR-125a [<xref rid="B8" ref-type="bibr">8</xref>], cytotoxic T lymphocyte-associated protein 4 (<italic>CTLA4</italic>), and human leukocyte antigen (<italic>HLA</italic>) [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Interferon (IFN) regulatory factors (IRFs), namely, transcriptional regulators of type I IFNs and IFN-inducible genes, play a pivotal role in innate and adaptive immune responses [<xref rid="B10" ref-type="bibr">10</xref>]. IRF7, a member of the IRF family, is required for type I IFN production and can regulate type I IFN-dependent immune responses [<xref rid="B11" ref-type="bibr">11</xref>]. Recent studies have indicated that polymorphisms in <italic>IRF7</italic> gene are associated with immunity-mediated diseases, systemic lupus erythematosus (SLE) [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>] and systemic sclerosis [<xref rid="B14" ref-type="bibr">14</xref>]. These studies have contributed to understanding the relationship between the <italic>IRF7</italic> gene mutations and the risk of autoimmune disease, but it is unknown whether <italic>IRF7</italic> gene variations increase or decrease the susceptibility to AITDs.</p><p>The purpose of this case-control study was to explore the association of <italic>IRF7</italic> gene polymorphisms with AITDs in a Chinese Han population. Furthermore, we analyzed the correlation between genotypes of <italic>IRF7</italic> gene and AITD clinical phenotypes.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Subjects</title><p>A total of 1659 subjects consisting of 889 AITD patients (220 males and 669 females; mean age of 36.29 &#177; 14.31 years) and 770 controls (216 males and 544 females; mean age of 39.04 &#177; 8.79 years) were enrolled in this study. The AITD patients were clinically subdivided into 592 GD (179 males and 413 females; mean age of 36.95 &#177; 14.70 years) and 297 HT (41 males and 256 females; mean age of 34.96 &#177; 13.42 years). All the AITD patients were recruited from the Outpatient Department of Endocrinology of Jinshan Hospital of Fudan University. GD was diagnosed based on hyperthyroidism and the positive circulating thyroid stimulating hormone receptor antibody (TRAb). HT was defined by high level of positive antibody against thyroid peroxidase (TPOAb) or thyroglobulin (TGAb), with or without hypothyroidism and the presence of an enlarged thyroid.</p><p>The controls were healthy individuals recruited from the Check-Up Center of the same hospital. Those controls with any autoimmune disease or family history of thyroid diseases were excluded. All subjects were of Chinese Han ethnicity. The written informed consent was obtained from all the participants. This study was approved by the ethics committee of the hospital.</p><p>The clinical phenotypes of AITD patients included the presence or absence of family history within three generations, with or without ophthalmopathy, the onset age (&#8804;18 years vs. &#8805;19 years), euthyroid status, or hypothyroidism in HT patients.</p></sec><sec id="sec2.2"><title>2.2. Genomic DNA Extraction</title><p>We obtained 2&#8201;mL of peripheral venous blood from all the subjects by venipuncture and then extracted genomic DNA using RelaxGene Blood DNA System (Tiangen Biotech, Beijing, China) according to the manufacturer's guidelines. The concentration and purity of DNA from each sample were detected using NanoDrop 2000 Spectrophotometer (Thermo Scientific Company, Waltham, USA).</p></sec><sec id="sec2.3"><title>2.3. SNP Selection and Genotyping</title><p>We selected three loci of rs1061501, rs1131665, and rs1061502 in the <italic>IRF7</italic> region because of their strong association with other autoimmune diseases like SLE and systemic sclerosis [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>]. Furthermore, marker-tagging SNPs had to meet the criteria of minor allele frequency (MAF) &gt; 0.01, Hardy&#8211;Weinberg equilibrium (HWE) with <italic>P</italic> &gt; 0.01, and logarithm of odds (LOD) &gt; 3.0.</p><p>The genotyping of three SNPs of <italic>IRF7</italic> was performed using ligase detection reactions (LDR) platform [<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>].</p></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>All statistical analyses were performed using SPSS software (version 17.0).</p><p>The clinical data of the subjects are presented as M &#177; SD. The differences in genotype and allele frequency distributions were analyzed by <italic>&#967;</italic><sup>2</sup> test or Fisher's exact test. HWE test, linkage disequilibrium (LD), and haplotype frequency were performed using HaploView 4.2. Odds ratio (OR) and 95% confidence interval (CI) were calculated for the association of genotype or allele frequencies with AITDs.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Clinical Data Analysis</title><p>Clinical data of all the subjects were summarized in <xref rid="tab1" ref-type="table">Table 1</xref>. Our study investigated 889 AITD patients, consisting of 592 GD patients (30.24% males and 69.76% females; mean age of 36.95 &#177; 14.70 years) and 297 HT ones (13.80% males and 86.20% females; mean age of 34.96 &#177; 13.42 years). Among the AITDs patients, there were 181 (20.36%) cases with a family history, 111 (12.49%) cases with ophthalmopathy, and 161 (13.72%) cases who were teenager patients with an onset age of &#8804;18 years old. Among the GD patients, 120 individuals had a family history, 106 had ophthalmopathy, and 83 with an onset age of &#8804;18 years old (20.27%, 17.91%, and 14.02%, respectively). While in the HT patients, 61 individuals had a family history, 5 had ophthalmopathy and 39 with an onset age of &#8804;18 years old (20.54%, 1.68%, and 13.13%, respectively).</p></sec><sec id="sec3.2"><title>3.2. Allele and Genotypic Results</title><p>The genotype distributions of these three SNPs (rs1061501/rs1131665/rs1061502) were in Hardy&#8211;Weinberg equilibrium (<italic>P</italic> &gt; 0.05) in both AITD patients and controls (data not shown). Differences in genotypic and allelic frequencies of these three SNPs between AITD patients and controls were compared (<xref rid="tab2" ref-type="table">Table 2</xref>). For rs1131665, the AG genotype frequency and the minor allele G frequency in AITD patients were both significantly higher than those of the controls (AG genotype: 4.5% vs. 2.3%, <italic>P</italic> = 0.017, OR = 1.968, 95% CI = 1.119-3.463; allele G: 2.2% vs. 1.2%, <italic>P</italic> = 0.018, OR = 1.946, 95% CI = 1.111-3.409). Similar trend was also found for rs1061502. However, no significant differences in both allele and genotype frequencies of rs1061501 were found between AITD patients and the controls.</p><p>As shown in <xref rid="tab3" ref-type="table">Table 3</xref>, subgroup analysis showed that the AG genotype frequency of rs1131665 and rs1061502 in GD patients was significantly higher than that of the controls (<italic>P</italic> = 0.015, OR = 2.074, 95% CI = 1.136-3.787; <italic>P</italic> = 0.034, OR = 1.919, 95% CI = 1.042-3.535, respectively). The minor allele G frequency of rs1131665 and rs1061502 in GD patients was also significantly higher than that of the controls (<italic>P</italic> = 0.016, OR = 2.048, 95% CI = 1.127-3.721; <italic>P</italic> = 0.035, OR = 1.898, 95% CI = 1.036-3.479, respectively). No significant difference in the three SNPs, however, was found between HT patients and the controls.</p></sec><sec id="sec3.3"><title>3.3. Genotype and Clinical Phenotype Correlations</title><p>We also analyzed the association of genotypes with clinical phenotypes, including age of onset (&#8804;18 years old or &#8805;19 years old) in AITD patients, with or without ophthalmopathy in GD patients, hypothyroidism, or euthyroidism in HT patients.</p><p>
<xref rid="tab4" ref-type="table">Table 4</xref> displayed that the allele G frequency of rs1061501 in GD patients with ophthalmopathy was significantly higher than that of GD patients without ophthalmopathy (<italic>P</italic> = 0.035, OR = 1.396, 95% CI = 1.023-1.906). As shown in Tables <xref rid="tab5" ref-type="table">5</xref> and <xref rid="tab6" ref-type="table">6</xref>, we did not find any difference in specific genotype frequency or allele frequency in AITD patients with different age of disease onset, also in HT patients accompanied with hypothyroidism or not (all <italic>P</italic> &gt; 0.05).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>To our knowledge, the present study was the first to investigate the association of <italic>IRF7</italic> polymorphisms with the susceptibility to AITDs. Our results showed that AG genotype and the minor G allele of rs1131665 and rs1061502 significantly increased the risk of AITDs and GD. More importantly, the minor G allele of rs1061501 was associated with ophthalmopathy in GD patients.</p><p>In concordance with our study, Fu et al. have shown that the polymorphisms of rs1131665 in <italic>IRF7</italic> conferred susceptibility to the development of SLE in multiple ethnic groups, including Asians, Chinese, and European Americans. Moreover, their meta-analysis provided direct genetic evidence that <italic>IRF7</italic> is a risk gene for human SLE [<xref rid="B18" ref-type="bibr">18</xref>]. Another study involving 2316 SSc patients and 2347 healthy controls demonstrated a significant association of rs1131665 polymorphisms with the presence of anticentromere autoantibodies (ACA) in SSc patients [<xref rid="B14" ref-type="bibr">14</xref>]. The TT genotype and T allele of rs1061501 in <italic>IRF7</italic> were also found to be associated with an increased risk of developing SLE among Taiwanese patients, but no significant difference in rs1061502 SNP was found between SLE patients and controls [<xref rid="B13" ref-type="bibr">13</xref>]. One possible explanation is that their small sample size (92 SLE patients and 92 healthy controls) caused lower statistical power.</p><p>
<italic>IRF7</italic> is localized on human chromosome 11p15.5 and interacts with the MyD88 adaptor protein downstream of Toll-like receptor (TLR) signaling [<xref rid="B19" ref-type="bibr">19</xref>]. <italic>IRF7</italic> can induce a large amount of type I IFN after being activated by TLR7 and TLR9 in plasmacytoid dendritic cells [<xref rid="B20" ref-type="bibr">20</xref>]. Interferon- (INF-) <italic>&#945;</italic>, a type 1 INF, is widely used to treat chronic hepatitis C for its antiviral effects [<xref rid="B21" ref-type="bibr">21</xref>]. Furthermore, INF-<italic>&#945;</italic> is also strongly linked with the occurrence of AITDs because it can evoke antibody-mediated immune responses [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. One study revealed that overt AITD occurred in about 5&#8211;10% of INF-<italic>&#945;</italic>-treated patients [<xref rid="B24" ref-type="bibr">24</xref>]. A recent study has also found that 2% of patients developed hyperthyroidism in the HCV-positive patients during a 12-week course of INF-<italic>&#945;</italic> antiviral therapy [<xref rid="B25" ref-type="bibr">25</xref>]. Therefore, studies have indicated that INF-<italic>&#945;</italic> is one of the important immune factors that induce AITDs [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>].</p><p>Our results demonstrated that the AG genotype and minor allele G frequency of rs1131665 and rs1061502 in AITD patients and GD patients were both significantly higher than those of the controls, suggesting that minor allele G may be a risk factor for AITD and GD. However, neither the genotype nor allele of rs1131665, rs1061501, and rs1061502 was found to be associated with HT, indicating that the three SNPs were not involved in the pathogenesis of HT. These different results of the <italic>IRF7</italic> SNPs in GD and HT may be attributed to their different etiology. Intriguingly, the further genotyping-clinical phenotype correlation analysis showed that the allele G frequency of rs1061501 in GD patients with ophthalmopathy was significantly higher than that of GD patients without ophthalmopathy, conferring a significant degree of risk for ophthalmopathy in GD patients. Graves' ophthalmopathy, a common extrathyroidal manifestation of GD, affects 25-50% of GD patients to various extent [<xref rid="B28" ref-type="bibr">28</xref>]. To date, its etiology remains unclear. To our knowledge, some genes have been related to Graves' ophthalmopathy, such as thyroid-stimulating hormone receptor (TSHR), <italic>CTLA-4</italic>, <italic>HLA-DRB-1</italic>, and <italic>TNF-&#945;</italic> [<xref rid="B29" ref-type="bibr">29</xref>&#8211;<xref rid="B31" ref-type="bibr">31</xref>]. Our results suggested the association of <italic>IRF7</italic> polymorphisms with Graves' ophthalmopathy, thus adding <italic>IRF7</italic> to the list of predisposing genes of Graves' ophthalmopathy. But according to our existing data, we cannot evaluate the association of IRF7 polymorphisms with the clinical activity, severity, and response to treatment of Graves' ophthalmopathy, which needs to be further studied in the future.</p><p>Above all, our study was the first to investigate the association of <italic>IRF7</italic> gene polymorphisms with the susceptibility to AITD. Our study suggests that <italic>IRF7</italic> is a crucial risk factor for AITD and GD. Further researches aiming at identifying the function and mechanism of IRF7 in AITDs are needed to be conducted. Our results are needed to perform in other population. In addition, more attention should be paid to other loci of <italic>IRF7</italic> and the potential roles of <italic>IRF7</italic> in other autoimmune diseases.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank all of the people who took part in the studies. This project was supported by grants from the National Natural Science Foundation of China (81471004, 81670722).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data analyzed during this study have been provided in the manuscript and any further information can be made available on request to the corresponding author.</p></sec><sec><title>Conflicts of Interest</title><p>The authors declare no competing interest and are responsible for the content and writing of the article.</p></sec><sec><title>Authors' Contributions</title><p>Qiuming Yao conducted the research and wrote the manuscript. Qiuming Yao and Xiaofei An analyzed the data. Xiaofei An, Jing Zhang, Kaida Mu, Ling Li, and Ronghua Song contributed to the recruitment of the subject and the collection of the clinical data. Peilong Sun and Jin-an Zhang designed the study and corrected the manuscript. All authors approved the final manuscript.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>A.</given-names></name><name><surname>Ferrari</surname><given-names>S. M.</given-names></name><name><surname>Corrado</surname><given-names>A.</given-names></name><name><surname>di Domenicantonio</surname><given-names>A.</given-names></name><name><surname>Fallahi</surname><given-names>P.</given-names></name></person-group><article-title>Autoimmune thyroid disorders</article-title><source><italic toggle="yes">Autoimmunity Reviews</italic></source><year>2015</year><volume>14</volume><issue>2</issue><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2014.10.016</pub-id><pub-id pub-id-type="other">2-s2.0-84922526985</pub-id><?supplied-pmid 25461470?><pub-id pub-id-type="pmid">25461470</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burch</surname><given-names>H. B.</given-names></name><name><surname>Cooper</surname><given-names>D. S.</given-names></name></person-group><article-title>Management of Graves disease: a review</article-title><source><italic toggle="yes">JAMA</italic></source><year>2015</year><volume>314</volume><issue>23</issue><fpage>2544</fpage><lpage>2554</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.16535</pub-id><pub-id pub-id-type="other">2-s2.0-84950162371</pub-id><?supplied-pmid 26670972?><pub-id pub-id-type="pmid">26670972</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiersinga</surname><given-names>W. M.</given-names></name></person-group><article-title>Thyroid autoimmunity</article-title><source><italic toggle="yes">Endocrine Development</italic></source><year>2014</year><volume>26</volume><fpage>139</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1159/000363161</pub-id><pub-id pub-id-type="other">2-s2.0-84958659377</pub-id><pub-id pub-id-type="pmid">25231450</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Leo</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name><name><surname>Braverman</surname><given-names>L. E.</given-names></name></person-group><article-title>Hyperthyroidism</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2016</year><volume>388</volume><issue>10047</issue><fpage>906</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00278-6</pub-id><pub-id pub-id-type="other">2-s2.0-84962050589</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thewjitcharoen</surname><given-names>Y.</given-names></name><name><surname>Krittiyawong</surname><given-names>S.</given-names></name><name><surname>Porramatikul</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A study of serum IgG4 levels in the clinical metamorphosis of autoimmune thyroid disease</article-title><source><italic toggle="yes">Journal of Clinical &amp; Translational Endocrinology</italic></source><year>2017</year><volume>8</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jcte.2017.05.002</pub-id><pub-id pub-id-type="other">2-s2.0-85019258990</pub-id><pub-id pub-id-type="pmid">29067257</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Mou</surname><given-names>Y.</given-names></name></person-group><article-title>Role of different CD40 polymorphisms in Graves&#8217; disease and Hashimoto&#8217;s thyroiditis</article-title><source><italic toggle="yes">Immunological Investigations</italic></source><year>2017</year><volume>46</volume><issue>6</issue><fpage>544</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1080/08820139.2017.1319382</pub-id><pub-id pub-id-type="other">2-s2.0-85025813782</pub-id><pub-id pub-id-type="pmid">28742400</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>J. H.</given-names></name><name><surname>Song</surname><given-names>G. G.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Choi</surname><given-names>S. J.</given-names></name></person-group><article-title>Association of interleukin 10 gene polymorphisms with autoimmune thyroid disease: meta-analysis</article-title><source><italic toggle="yes">Scandinavian Journal of Immunology</italic></source><year>2016</year><volume>84</volume><issue>5</issue><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/sji.12470</pub-id><pub-id pub-id-type="other">2-s2.0-84992461108</pub-id><pub-id pub-id-type="pmid">27500787</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>An</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Polymorphisms in MIR499A and MIR125A gene are associated with autoimmune thyroid diseases</article-title><source><italic toggle="yes">Molecular and Cellular Endocrinology</italic></source><year>2017</year><volume>440</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2016.11.017</pub-id><pub-id pub-id-type="other">2-s2.0-85000761549</pub-id><pub-id pub-id-type="pmid">27888002</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramgopal</surname><given-names>S.</given-names></name><name><surname>Rathika</surname><given-names>C.</given-names></name><name><surname>Padma</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>Interaction of HLA-DRB1<sup>&#8727;</sup> alleles and CTLA4 (+49 AG) gene polymorphism in autoimmune thyroid disease</article-title><source><italic toggle="yes">Gene</italic></source><year>2018</year><volume>642</volume><fpage>430</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2017.11.057</pub-id><pub-id pub-id-type="other">2-s2.0-85035079694</pub-id><pub-id pub-id-type="pmid">29174716</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>T.</given-names></name><name><surname>Yanai</surname><given-names>H.</given-names></name><name><surname>Savitsky</surname><given-names>D.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name></person-group><article-title>The IRF family transcription factors in immunity and oncogenesis</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2008</year><volume>26</volume><issue>1</issue><fpage>535</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090400</pub-id><pub-id pub-id-type="other">2-s2.0-42649114059</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K.</given-names></name><name><surname>Yanai</surname><given-names>H.</given-names></name><name><surname>Negishi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>IRF-7 is the master regulator of type-I interferon-dependent immune responses</article-title><source><italic toggle="yes">Nature</italic></source><year>2005</year><volume>434</volume><issue>7034</issue><fpage>772</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1038/nature03464</pub-id><pub-id pub-id-type="other">2-s2.0-17144404177</pub-id><pub-id pub-id-type="pmid">15800576</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Luan</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Association of genetic variations in the STAT4 and IRF7/KIAA1542 regions with systemic lupus erythematosus in a northern Han Chinese population</article-title><source><italic toggle="yes">Human Immunology</italic></source><year>2011</year><volume>72</volume><issue>3</issue><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2010.12.011</pub-id><pub-id pub-id-type="other">2-s2.0-79651468909</pub-id><pub-id pub-id-type="pmid">21167895</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L. H.</given-names></name><name><surname>Ling</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>M. F.</given-names></name></person-group><article-title>The potential role of interferon-regulatory factor 7 among Taiwanese patients with systemic lupus erythematosus</article-title><source><italic toggle="yes">The Journal of Rheumatology</italic></source><year>2011</year><volume>38</volume><issue>9</issue><fpage>1914</fpage><lpage>1919</lpage><pub-id pub-id-type="doi">10.3899/jrheum.101004</pub-id><pub-id pub-id-type="other">2-s2.0-80052328859</pub-id><pub-id pub-id-type="pmid">21632682</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona</surname><given-names>F. D.</given-names></name><name><surname>Gutala</surname><given-names>R.</given-names></name><name><surname>Sime&#243;n</surname><given-names>C. P.</given-names></name><etal/></person-group><article-title>Novel identification of the <italic>IRF7</italic> region as an anticentromere autoantibody propensity locus in systemic sclerosis</article-title><source><italic toggle="yes">Annals of the Rheumatic Diseases</italic></source><year>2012</year><volume>71</volume><issue>1</issue><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200275</pub-id><pub-id pub-id-type="other">2-s2.0-82955245641</pub-id><?supplied-pmid 21926187?><pub-id pub-id-type="pmid">21926187</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Polymorphisms of IKZF3 gene and autoimmune thyroid diseases: associated with Graves&#8217; disease but not with Hashimoto&#8217;s thyroiditis</article-title><source><italic toggle="yes">Cellular Physiology and Biochemistry</italic></source><year>2018</year><volume>45</volume><issue>5</issue><fpage>1787</fpage><lpage>1796</lpage><pub-id pub-id-type="doi">10.1159/000487870</pub-id><pub-id pub-id-type="other">2-s2.0-85044739233</pub-id><pub-id pub-id-type="pmid">29510406</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>R. H.</given-names></name><name><surname>Qin</surname><given-names>Q.</given-names></name><name><surname>Yan</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Variants in IRAK1-MECP2 region confer susceptibility to autoimmune thyroid diseases</article-title><source><italic toggle="yes">Molecular and Cellular Endocrinology</italic></source><year>2015</year><volume>399</volume><fpage>244</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2014.10.013</pub-id><pub-id pub-id-type="other">2-s2.0-84910091397</pub-id><pub-id pub-id-type="pmid">25458699</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>N.</given-names></name><name><surname>Meng</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>R. H.</given-names></name><etal/></person-group><article-title>Polymorphism of IL37 gene as a protective factor for autoimmune thyroid disease</article-title><source><italic toggle="yes">Journal of Molecular Endocrinology</italic></source><year>2015</year><volume>55</volume><issue>3</issue><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1530/JME-15-0144</pub-id><pub-id pub-id-type="other">2-s2.0-84947805303</pub-id><pub-id pub-id-type="pmid">26373794</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Qian</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Association of a functional IRF7 variant with systemic lupus erythematosus</article-title><source><italic toggle="yes">Arthritis and Rheumatism</italic></source><year>2011</year><volume>63</volume><issue>3</issue><fpage>749</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1002/art.30193</pub-id><pub-id pub-id-type="other">2-s2.0-79953707345</pub-id><pub-id pub-id-type="pmid">21360504</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paun</surname><given-names>A.</given-names></name><name><surname>Pitha</surname><given-names>P. M.</given-names></name></person-group><article-title>The IRF family, revisited</article-title><source><italic toggle="yes">Biochimie</italic></source><year>2007</year><volume>89</volume><issue>6-7</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2007.01.014</pub-id><pub-id pub-id-type="other">2-s2.0-34347244891</pub-id><pub-id pub-id-type="pmid">17399883</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name></person-group><article-title>IRFs: master regulators of signalling by toll-like receptors and cytosolic pattern-recognition receptors</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2006</year><volume>6</volume><issue>9</issue><fpage>644</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nri1900</pub-id><pub-id pub-id-type="other">2-s2.0-33748051738</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandac</surname><given-names>J. C.</given-names></name><name><surname>Chaudhry</surname><given-names>S.</given-names></name><name><surname>Sherman</surname><given-names>K. E.</given-names></name><name><surname>Tomer</surname><given-names>Y.</given-names></name></person-group><article-title>The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification</article-title><source><italic toggle="yes">Hepatology</italic></source><year>2006</year><volume>43</volume><issue>4</issue><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1002/hep.21146</pub-id><pub-id pub-id-type="other">2-s2.0-33645986654</pub-id><pub-id pub-id-type="pmid">16557537</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>M. W.</given-names></name><name><surname>Fried</surname><given-names>M. W.</given-names></name></person-group><article-title>Side effects of therapy for chronic hepatitis C</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2003</year><volume>124</volume><issue>6</issue><fpage>1711</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(03)00394-9</pub-id><pub-id pub-id-type="other">2-s2.0-0037517079</pub-id><pub-id pub-id-type="pmid">12761728</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burman</surname><given-names>P.</given-names></name><name><surname>T&#246;tterman</surname><given-names>T. H.</given-names></name><name><surname>&#214;berg</surname><given-names>K.</given-names></name><name><surname>Anders Karlsson</surname><given-names>F.</given-names></name></person-group><article-title>Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon</article-title><source><italic toggle="yes">The Journal of Clinical Endocrinology &amp; Metabolism</italic></source><year>1986</year><volume>63</volume><issue>5</issue><fpage>1086</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1210/jcem-63-5-1086</pub-id><pub-id pub-id-type="other">2-s2.0-0022981391</pub-id><?supplied-pmid 2944910?><pub-id pub-id-type="pmid">2944910</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J. D.</given-names></name><name><surname>Wang</surname><given-names>Y. H.</given-names></name><name><surname>Liu</surname><given-names>C. H.</given-names></name><etal/></person-group><article-title>Association of IRF8 gene polymorphisms with autoimmune thyroid disease</article-title><source><italic toggle="yes">European Journal of Clinical Investigation</italic></source><year>2015</year><volume>45</volume><issue>7</issue><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1111/eci.12463</pub-id><pub-id pub-id-type="other">2-s2.0-84933279687</pub-id><pub-id pub-id-type="pmid">25989711</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>G.</given-names></name><name><surname>Panag</surname><given-names>K.</given-names></name><name><surname>Garg</surname><given-names>R.</given-names></name></person-group><article-title>Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy</article-title><source><italic toggle="yes">International Journal of Applied &amp; Basic Medical Research</italic></source><year>2016</year><volume>6</volume><issue>4</issue><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.4103/2229-516X.192587</pub-id><pub-id pub-id-type="pmid">27857890</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomer</surname><given-names>Y.</given-names></name></person-group><article-title>Hepatitis C and interferon induced thyroiditis</article-title><source><italic toggle="yes">Journal of Autoimmunity</italic></source><year>2010</year><volume>34</volume><issue>3</issue><fpage>J322</fpage><lpage>J326</lpage><pub-id pub-id-type="doi">10.1016/j.jaut.2009.11.008</pub-id><pub-id pub-id-type="other">2-s2.0-77649192926</pub-id><pub-id pub-id-type="pmid">20022216</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomer</surname><given-names>Y.</given-names></name><name><surname>Blackard</surname><given-names>J. T.</given-names></name><name><surname>Akeno</surname><given-names>N.</given-names></name></person-group><article-title>Interferon alpha treatment and thyroid dysfunction</article-title><source><italic toggle="yes">Endocrinology and Metabolism Clinics of North America</italic></source><year>2007</year><volume>36</volume><issue>4</issue><fpage>1051</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1016/j.ecl.2007.07.001</pub-id><pub-id pub-id-type="other">2-s2.0-35648940270</pub-id><pub-id pub-id-type="pmid">17983936</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartalena</surname><given-names>L.</given-names></name><name><surname>Baldeschi</surname><given-names>L.</given-names></name><name><surname>Boboridis</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The 2016 European Thyroid Association/European Group on Graves&#8217; Orbitopathy guidelines for the management of Graves&#8217; orbitopathy</article-title><source><italic toggle="yes">European Thyroid Journal</italic></source><year>2016</year><volume>5</volume><issue>1</issue><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1159/000443828</pub-id><pub-id pub-id-type="pmid">27099835</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalilzadeh</surname><given-names>O.</given-names></name><name><surname>Noshad</surname><given-names>S.</given-names></name><name><surname>Rashidi</surname><given-names>A.</given-names></name><name><surname>Amirzargar</surname><given-names>A.</given-names></name></person-group><article-title>Graves&#8217; ophthalmopathy: a review of immunogenetics</article-title><source><italic toggle="yes">Current Genomics</italic></source><year>2011</year><volume>12</volume><issue>8</issue><fpage>564</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.2174/138920211798120844</pub-id><pub-id pub-id-type="other">2-s2.0-82055197106</pub-id><pub-id pub-id-type="pmid">22654556</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>CTLA4 polymorphisms and ophthalmopathy in Graves&#8217; disease patients: association study and meta-analysis</article-title><source><italic toggle="yes">Human Immunology</italic></source><year>2006</year><volume>67</volume><issue>8</issue><fpage>618</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2006.05.003</pub-id><pub-id pub-id-type="other">2-s2.0-33746985499</pub-id><pub-id pub-id-type="pmid">16916658</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurecka-Lubieniecka</surname><given-names>B.</given-names></name><name><surname>Ploski</surname><given-names>R.</given-names></name><name><surname>Kula</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Association between polymorphisms in the <italic>TSHR</italic> gene and Graves&#8217; orbitopathy</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2014</year><volume>9</volume><issue>7, article e102653</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0102653</pub-id><pub-id pub-id-type="other">2-s2.0-84905000189</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical data of all subjects.</p></caption><table-wrap-foot><fn><p>AITD, autoimmune thyroid disease; GD, Graves' disease; HT, Hashimoto's thyroiditis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Allele and genotype frequencies of <italic>IRF7</italic> SNPs in controls and AITD patients.</p></caption><table-wrap-foot><fn><p>AITD, autoimmune thyroid disease; OR, odds ratio; 95% CI, 95% confidence intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Allele and genotype frequencies of <italic>IRF7</italic> SNPs in GD, HT patients, and controls.</p></caption><table-wrap-foot><fn><p>GD, Graves' disease; HT, Hashimoto's thyroiditis; OR, odds ratio; 95% CI, 95% confidence intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>
<italic>IRF7</italic> genotype and allele distribution in ophthalmopathy or nonophthalmopathy GD patients.</p></caption><table-wrap-foot><fn><p>GD, Graves' disease; OR, odds ratio; 95% CI, 95% confidence intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Allele and genotype distribution of <italic>IRF7</italic> in AITDs patients with or without early onset age.</p></caption><table-wrap-foot><fn><p>AITD, autoimmune thyroid disease; OR, odds ratio; 95% CI, 95% confidence intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>
<italic>IRF7</italic> genotype and allele distribution in clinical subphenotype of HT patients.</p></caption><table-wrap-foot><fn><p>HT, Hashimoto's thyroiditis; OR, odds ratio; 95% CI, 95% confidence intervals.</p></fn></table-wrap-foot></table-wrap></floats-group></article>